Wu J, Huang J, Zhu G, et al. - Given that many treatment guidelines now recommend systemic corticosteroids but supporting evidence is limited to 1 randomized controlled clinical trial (RECOVERY), therefore, researchers investigated if corticosteroids have beneficial impacts in patients suffering from coronavirus disease 2019 (COVID-19). This analysis involved 1,514 severe and 249 critical hospitalized COVID-19 patients. The participants were recruited from 2 medical centers in Wuhan, China. Findings demonstrated no beneficial impact of corticosteroid use in attenuating in-hospital mortality for severe or critical cases in Wuhan. This finding is in contrast to that noted in the RECOVERY clinical trial, and the likely reasons for this revelation are: biases in observational data, in particular prescription by indication bias, variations in clinical features of patients, choice of corticosteroid employed, timing of start of treatment, and treatment span.